Immunosuppressive effect of 2'-deoxycoformycin (Pentostatin) for rat islet allotransplantation. 1995

A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75235-9031, USA.

Adenosine deaminase (ADA) is an important enzyme for proper function of lymphocytes and congenital absence of ADA results in a form of severe combined immunodeficiency syndrome. 2'-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug. The present study evaluated the immunosuppressive effect of DCF for islet allotransplantation in rats. Isolated islets (1,500 islets) from Lewis rats were transplanted into the kidney subcapsular space of streptozotocin-induced diabetic Wistar-Furth rats. DCF was administered IP either as a single injection at 1 mg/kg/wk, 1 mg/kg twice weekly, 5 mg/kg/twice weekly or 1 mg/kg/day, or as a continuous infusion at 0.8 or 1 mg/kg/day. Daily administration of DCF at 0.8 mg/kg in both methods, single daily injection or continuous infusion, resulted in a lymphopenia and a decrease in concanavalin A stimulation of splenic lymphocytes. However, DCF (in all doses) was not effective in preventing islet allograft rejection as evaluated by measuring the duration of normoglycemia following islet transplantation and by microscopic examination of the islet grafts. In fact, the duration of normoglycemia following islet transplantation was 7.5 +/- 0.9 and 9.0 +/- 1.0 days in rats receiving DCF in single daily injection or continuous infusion, respectively. This was not significantly different from control nontreated transplanted rats (8.5 +/- 0.7 days). Increasing the dose of DCF to 1 mg/kg, administered by continuous infusion, resulted in 100% mortality. For comparison, cyclosporine A (20 mg/kg, IP daily injection for 14 days) prolonged islet allograft survival to 27.3 +/- 1.5 days (p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D015649 Pentostatin A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. 2'-Deoxycoformycin,CI-825,Co-Vidarabine,Deoxycoformycin,Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)-,NSC-218321,Nipent,2' Deoxycoformycin,CI 825,CI825,NSC 218321,NSC218321

Related Publications

A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
January 1989, Bone marrow transplantation,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
September 1990, Cancer treatment reviews,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
April 1999, British journal of haematology,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
April 1986, Cancer treatment reports,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
February 2006, Leukemia & lymphoma,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
February 1984, Scandinavian journal of haematology,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
April 1987, The New England journal of medicine,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
October 1988, Journal of the American Academy of Dermatology,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
September 1991, Teratology,
A Ar'Rajab, and R B Harris, and T A Khair-el-Din, and J T Sentementes, and C Lu, and I J Dawidson
March 2005, Haematologica,
Copied contents to your clipboard!